Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
出版年份 2021 全文链接
标题
Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
作者
关键词
-
出版物
Diabetes Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-11
DOI
10.1007/s13300-021-01018-w
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The Place of Sulfonylureas in Guidelines: Why Are There Differences?
- (2020) Aslam Amod Diabetes Therapy
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management
- (2019) Stephanie A Amiel et al. Lancet Diabetes & Endocrinology
- Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies
- (2019) Jie Liu et al. Diabetes & Vascular Disease Research
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015
- (2019) Amanda K. Kitten et al. PLoS One
- A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm
- (2019) Matthew C. Riddle DIABETES CARE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
- (2018) Richard E. Pratley et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
- (2018) Ronnie Aronson et al. DIABETES OBESITY & METABOLISM
- Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
- (2018) Sam Miller et al. Diabetes Therapy
- Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
- (2018) Sam Miller et al. Diabetes Therapy
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
- (2018) Christopher P. Cannon et al. AMERICAN HEART JOURNAL
- Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus
- (2018) Gojka Roglic et al. ANNALS OF INTERNAL MEDICINE
- Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
- (2018) Dan Qian et al. PLoS One
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
- (2017) Priscilla Hollander et al. Diabetes Therapy
- Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
- (2017) George Grunberger et al. Diabetes Therapy
- Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
- (2017) Priscilla Hollander et al. Diabetes Therapy
- Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
- (2017) George Grunberger et al. Diabetes Therapy
- Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
- (2016) Steve Bain et al. DIABETES OBESITY & METABOLISM
- State of the art paper Sulfonylureas and their use in clinical practice
- (2015) Daniele Sola et al. Archives of Medical Science
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
- (2015) Greg Fulcher et al. Diabetes Therapy
- Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
- (2015) Greg Fulcher et al. Diabetes Therapy
- Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!: Table 1
- (2014) Martin J. Abrahamson DIABETES CARE
- Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On!
- (2014) Saul Genuth DIABETES CARE
- Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
- (2014) M. A. Nauck et al. DIABETES OBESITY & METABOLISM
- Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study
- (2014) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis
- (2008) J. Belsey et al. DIABETES OBESITY & METABOLISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now